Webinar: A Preclinical Systematic Exploration of Tumor Cell Vulnerabilities
Learn about how different tumor models can be used in applications from high-throughput screening to functional genomics to benefit translational cancer research.
Online
The capacity for data-driven science using multi-omic profiling of primary tumors and patient-derived cells to identify targets of interest for therapeutic development is vast in this modern era of computational science and artificial intelligence. Yet, candidate gene targets and drugs must be validated before entering expensive and time-consuming preclinical and clinical trials. In this webinar, we will discuss aspects of the preclinical drug development process, from target identification, to target selection and validation. Learn about how different tumor models can be used in applications from high-throughput screening to functional genomics to benefit translational cancer research.
Topics covered:
- Preclinical models for drug development and target validation
- Personalized therapy beyond mutation analysis
- Additivity vs synergy
- A functional genomics approach to target glioblastoma invasion
Speaker: Dr. Cecilia Krona - Uppsala University, Dept. of Immunology, Genetics and Pathology
Dr. Cecilia Krona is an Uppsala University neuro-oncology program researcher with a Ph.D. in medical genetics from the University of Gothenburg. During postdoctoral studies with Prof. Don W. Cleveland at the Ludwig Institute for Cancer Research, San Diego, she explored antisense oligonucleotide-based therapy for glioblastoma. In 2014, Dr. Krona joined Prof. Sven Nelander’s systems biology group at Uppsala University to establish and implement preclinical models based on a large collection of primary patient-derived cell cultures from glioblastoma tumors.
When: May 16, 2024, 16.00 CET
Where: Online (free)